Drug major Cipla, led by MD and CEO Umang Vohra, is entering India's weight management segment and strengthening its CNS ...

Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has ...

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...